SlidesetNTDAbstract #1 Population Pharmacokinetics of Tecovirimat in Persons with Mpox: Initial Results from ACTG A5418 - David NerguizianView Slideset
SlidesetCOVID-19Abstract #2 GS-443902 Concentrations in Peripheral Blood Mononuclear Cells and Dried Blood Spots among Pregnant and Non-Pregnant Women Receiving Remdesivir for COVID-19 Treatment - Alexandra DunbarView Slideset
SlidesetHIVHIV PEP in Clinical Practice: Guidelines and Real-World Complexities - Steve TaylorView Slideset
SlidesetHIVAbstract #3 Therapeutic Drug Monitoring of Dolutegravir in Children and Adolescents Living with HIV: A Retrospective Study - Émilie PiloteView Slideset
SlidesetHIVAbstract #4 Pharmacokinetic Parameters of Bictegravir in Breastmilk of Healthy, Lactating Volunteers without HIV After a Single Dose of 50mg (Co-Formulated with Emtricitabine 200mg and Tenofovir Alafenamide 25mg) - Lena Christina Wendy van der Wekken-PasView Slideset
SlidesetHIVAbstract #5 Plasma Bictegravir/Emtricitabine/Tenofovir Alafenamide Concentrations in Transgender Women with HIV on Estrogen-Based Gender-Affirming Hormone Therapy in Comparison to Cisgender Women Living with HIV - Shawnalyn SunagawaView Slideset
SlidesetAbstract #6 Target Attainment of Valganciclovir Prophylaxis against Cytomegalovirus - Suzanne WenkerView Slideset
SlidesetAbstract #7 An Enzymatic Assay for Rapid and Minimally Instrumented Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus - Willow ChernoskeView Slideset
SlidesetNIH Initiatives and Research Promoting Antiviral Pharmacology - Keith W. CrawfordView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Slideset
SlidesetTuberculosisAbstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Slideset
SlidesetHIVTuberculosisAbstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Slideset
SlidesetHIVTuberculosisAbstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Slideset
SlidesetHIVTuberculosisAbstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Slideset
SlidesetHIVAbstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Slideset
SlidesetHIVAbstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Slideset
SlidesetHIVAbstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Slideset
SlidesetHIVAbstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Slideset
SlidesetHIVAbstract #35 Can Low-Cost Oral Alternatives Be Used in Place of Oral Lenacapavir When Initiating Long-Acting Lenacapavir PrEP in Low- and Middle-Income Countries? - Andrew OwenView Slideset
SlidesetHIVAbstract #17 Lack of Clinically Significant Drug–Drug Interactions Between the Third-Generation Integrase Strand Transfer Inhibitor VH4524184 (VH-184) and Combined Oral Contraceptives - Jon CollinsView Slideset
SlidesetHIVAbstract #18 Antiviral Activity, Safety, and PK/PD of ACC017 in Antiretroviral Naïve HIV-Infected Adults: A Randomized, Double-Blind, Placebo/Dose-Parallel-Controlled Short-Term Monotherapy Study - Hong QinView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAbstract #19 Assessing ChatGPT’s Capability in Understanding and Reporting Antiretroviral Therapy Drug-Drug Interaction Effects: Quantitative and Qualitative Results from the ACCURATE-DDI Study - Erin ReadyView Slideset
SlidesetHIVAbstract #20 An Enzymatic Assay with Lateral Flow Readout for Measurement of Tenofovir Diphosphate and Long-Term HIV Medication Adherence - Carrie LinView Slideset
SlidesetHIVAbstract #21 Longitudinal Monitoring of Cabotegravir and Rilpivirine Exposure from Hair Strand Concentrations - Elias RosenView Slideset
SlidesetHIVCharles Boucher Memorial Lecture: Updates on Antiretroviral Penetration in Sanctuary Sites - Courtney V. FletcherView Slideset
SlidesetIntegration of Machine Learning for Predictive Pharmacometric Assessments - Soumitra SamantaView Slideset
SlidesetThe Role of MoAbs: Challenges in Prevention and Treatment of Infectious Diseases in Children - Alfredo TagarroView Slideset
SlidesetCurrent and Future Treatments in Cytomegalovirus: Maribavir, Letermovir, Vaccines, mABs - Per LjungmanView Slideset
